Posted by Michael Wonder on 06 Nov 2020
Additional analysis of Kyprolis in the treatment of multiple myeloma
6 November 2020 - TLV has performed an additional analysis of Kyprolis (carfilzomib) when used in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma.
The previous analysis concerned the treatment of adult patients who have previously received at least one treatment (no. 1068/2019).
The additional analysis only evaluates patients who are treated in the second-line, ie patients with multiple myeloma who have previously received a treatment, but not more.
